Calls for papers
-
According to GSK and Innoviva, the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI has been approved in Canada for the treatment of COPD in patients for whom treatment with an ICS/LABA combination is inadequate. Trelegy Ellipta should… Read more . . .
-
Sunovion Pharmaceuticals has launched Lonhala Magnair glycopyrrolate inhalation solution for the treatment of COPD in the US, the company said. Lonhala Magnair, also known as SUN-101/eFlow, was approved by the FDA in December 2017. In… Read more . . .
-
A Texas-based startup called TFF Pharmaceuticals announced that it raised $14 million in a Series A preferred stock offering and that it plans to use the funds for development of dry powder formulations for the… Read more . . .
-
Dr. Reddy’s subsidiary Promius Pharma has submitted an NDA for its DFN-02 intranasal sumatriptan for the treatment of migraine headaches, the company said. The DFN-02 formulation includes Aegis Therapeutics’ Intravail absorption enhancer; Aegis received a… Read more . . .
-
Insmed has submitted an NDA for ALIS amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC), the company said. In September 2017, Insmed announced that… Read more . . .
-
Boehringer Ingelheim has published results from the 52-week DYNAGITO study in The Lancet Respiratory Medicine showing that the Stiolto Respimat tiotropium bromide/olodaterol soft mist inhaler produced a 7% greater reduction in moderate-to-severe COPD exacerbations than… Read more . . .
-
According to Arch Biopartners, the US Patent and Trademark Office has issued US Patent 9,925,206, “Compositions and Methods for Treating Bacterial Infection,” which covers the composition of AB569 sodium nitrite/ethylenediaminetetraacetic acid (EDTA), to the University… Read more . . .
-
US-based Convexity Scientific has announced the availability of its Flyp handheld ultrasonic nebulizer, which the company says received FDA clearance in May 2017. The Flyp nebulizer is lighter weight than a smartphone, the company said,… Read more . . .
-
Verona Pharma has announced that a Phase 2b study of its RPL554 inhaled PDE3/PDE4 inhibitor met its primary endpoint, demonstrating significant improvement in FEV1 compared to placebo at 4 weeks in patients with moderate-to-severe COPD… Read more . . .
-
According to Adherium, the FDA has okayed over-the-counter (OTC) sales of the company’s Smartinhaler sensor for AstraZeneca’s Symbicort MDI. The 510(k) OTC clearance will allow patients to purchase the sensor without a prescription at local… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland